← board
TEVJF
distress 0/10 · well-funded / low risk$27.50-3%today-17% from 52w high
tevapharm.com31,173 employeesFounded 1901Tel Aviv-Yafo, IsraelDrug Manufacturers - Specialty & Generic
Revenue
$3982M
Liquidity
$3741M
Runway
—
Shares 1y
+2%
Price & events
-16.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.2%
1D
-16.7%
1W
-9.4%
1M
-3.0%
3M
-16.3%
6M
+96.4%
1Y
+80.1%
2Y
+187.7%
5Y
+192.6%
All
Overview
- Market Cap
- $32.02B
- Volume
- 7
- 52 Week Range
- $14.00 – $33.00
- Total Shares
- 1.16B
- Float Shares
- 1.08B
- % Held by Insiders
- 2.19%
- % Held by Institutions
- 21.40%
- RVOL
- 0.68x
- Beta
- 0.86
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-07-29Confirmed 100%earningsEarningsEarnings releaseyahoo
- 2026-04-29partnershipDefinitive agreement to acquire Emalex Biosciences.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-22Teva stock trades steady as biosimilars and generics underpin earnings trajectory - Ad-hoc-news.de
- 2026-07-19Teva stock trades steady as investors weigh recent cost measures and debt reduction progress - Ad-hoc-news.de
- 2026-07-19Teva stock’s downward trend continues - Globes - Israel Business News
- 2026-07-07Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results - The Manila Times
- 2026-07-07Teva Pharmaceutical Industries Ltd - Via Ritzau
- 2026-07-07Teva's vitiligo antibody advances after early skin-pigment gains - Stock Titan
- 2026-07-07Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results - Finansavisen
- 2026-06-24Teva submits NDA for ecopipam for pediatric Tourette syndrome - Contemporary Pediatrics
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.